Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus
Oxidative stress is enhanced by various mechanisms. Serum oxidized low-density lipoprotein (LDL) is a useful prognostic marker in diabetic patients with coronary artery disease. To examine the effects of Theracurmin®, a highly absorbable curcumin preparation, on glucose tolerance, adipocytokines, an...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2019/8208237 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691575341285376 |
|---|---|
| author | Masafumi Funamoto Kana Shimizu Yoichi Sunagawa Yasufumi Katanasaka Yusuke Miyazaki Hideaki Kakeya Hajime Yamakage Noriko Satoh-Asahara Hiromichi Wada Koji Hasegawa Tatsuya Morimoto |
| author_facet | Masafumi Funamoto Kana Shimizu Yoichi Sunagawa Yasufumi Katanasaka Yusuke Miyazaki Hideaki Kakeya Hajime Yamakage Noriko Satoh-Asahara Hiromichi Wada Koji Hasegawa Tatsuya Morimoto |
| author_sort | Masafumi Funamoto |
| collection | DOAJ |
| description | Oxidative stress is enhanced by various mechanisms. Serum oxidized low-density lipoprotein (LDL) is a useful prognostic marker in diabetic patients with coronary artery disease. To examine the effects of Theracurmin®, a highly absorbable curcumin preparation, on glucose tolerance, adipocytokines, and oxidized LDL, we conducted a double-blind placebo-controlled parallel group randomized trial in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus. We randomly divided the patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus and stable individuals into the placebo group and the Theracurmin® (180 mg daily for 6 months) group. Of the 33 patients analyzed, 18 (14 males and 4 females) were administered placebo and 15 (9 males and 6 females) were administered Theracurmin®. The patient characteristics did not differ between the two groups. The primary endpoint, HbA1c, did not differ significantly between the two groups. However, the level of α1-antitrypsin-low-density lipoprotein (AT-LDL), the oxidized LDL, significantly increased (p=0.024) in the placebo group from the beginning of the trial up to 6 months, although there was no such change in the Theracurmin® group. The percentage change in BMI from the beginning of the trial up to 6 months tended to be higher in the Theracurmin® group than in the placebo group. Patients in the Theracurmin® group tended to have a larger percentage change in adiponectin and LDL-C than those in the placebo group. Patients in the Theracurmin® group showed a smaller percentage change in AT-LDL than those in the placebo group. This study suggests that the highly absorbable curcumin could potentially inhibit a rise in oxidized LDL in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus. This trial is registered with UMIN000007361. |
| format | Article |
| id | doaj-art-e2570173a5b84791a1eef44000dd6cd1 |
| institution | DOAJ |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-e2570173a5b84791a1eef44000dd6cd12025-08-20T03:20:59ZengWileyJournal of Diabetes Research2314-67452314-67532019-01-01201910.1155/2019/82082378208237Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes MellitusMasafumi Funamoto0Kana Shimizu1Yoichi Sunagawa2Yasufumi Katanasaka3Yusuke Miyazaki4Hideaki Kakeya5Hajime Yamakage6Noriko Satoh-Asahara7Hiromichi Wada8Koji Hasegawa9Tatsuya Morimoto10Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, JapanDepartment of System Chemotherapy and Molecular Sciences, Division of Bioinformatics and Chemical Genomics, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, JapanClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, JapanClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, JapanClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, JapanOxidative stress is enhanced by various mechanisms. Serum oxidized low-density lipoprotein (LDL) is a useful prognostic marker in diabetic patients with coronary artery disease. To examine the effects of Theracurmin®, a highly absorbable curcumin preparation, on glucose tolerance, adipocytokines, and oxidized LDL, we conducted a double-blind placebo-controlled parallel group randomized trial in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus. We randomly divided the patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus and stable individuals into the placebo group and the Theracurmin® (180 mg daily for 6 months) group. Of the 33 patients analyzed, 18 (14 males and 4 females) were administered placebo and 15 (9 males and 6 females) were administered Theracurmin®. The patient characteristics did not differ between the two groups. The primary endpoint, HbA1c, did not differ significantly between the two groups. However, the level of α1-antitrypsin-low-density lipoprotein (AT-LDL), the oxidized LDL, significantly increased (p=0.024) in the placebo group from the beginning of the trial up to 6 months, although there was no such change in the Theracurmin® group. The percentage change in BMI from the beginning of the trial up to 6 months tended to be higher in the Theracurmin® group than in the placebo group. Patients in the Theracurmin® group tended to have a larger percentage change in adiponectin and LDL-C than those in the placebo group. Patients in the Theracurmin® group showed a smaller percentage change in AT-LDL than those in the placebo group. This study suggests that the highly absorbable curcumin could potentially inhibit a rise in oxidized LDL in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus. This trial is registered with UMIN000007361.http://dx.doi.org/10.1155/2019/8208237 |
| spellingShingle | Masafumi Funamoto Kana Shimizu Yoichi Sunagawa Yasufumi Katanasaka Yusuke Miyazaki Hideaki Kakeya Hajime Yamakage Noriko Satoh-Asahara Hiromichi Wada Koji Hasegawa Tatsuya Morimoto Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus Journal of Diabetes Research |
| title | Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus |
| title_full | Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus |
| title_fullStr | Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus |
| title_full_unstemmed | Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus |
| title_short | Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus |
| title_sort | effects of highly absorbable curcumin in patients with impaired glucose tolerance and non insulin dependent diabetes mellitus |
| url | http://dx.doi.org/10.1155/2019/8208237 |
| work_keys_str_mv | AT masafumifunamoto effectsofhighlyabsorbablecurcumininpatientswithimpairedglucosetoleranceandnoninsulindependentdiabetesmellitus AT kanashimizu effectsofhighlyabsorbablecurcumininpatientswithimpairedglucosetoleranceandnoninsulindependentdiabetesmellitus AT yoichisunagawa effectsofhighlyabsorbablecurcumininpatientswithimpairedglucosetoleranceandnoninsulindependentdiabetesmellitus AT yasufumikatanasaka effectsofhighlyabsorbablecurcumininpatientswithimpairedglucosetoleranceandnoninsulindependentdiabetesmellitus AT yusukemiyazaki effectsofhighlyabsorbablecurcumininpatientswithimpairedglucosetoleranceandnoninsulindependentdiabetesmellitus AT hideakikakeya effectsofhighlyabsorbablecurcumininpatientswithimpairedglucosetoleranceandnoninsulindependentdiabetesmellitus AT hajimeyamakage effectsofhighlyabsorbablecurcumininpatientswithimpairedglucosetoleranceandnoninsulindependentdiabetesmellitus AT norikosatohasahara effectsofhighlyabsorbablecurcumininpatientswithimpairedglucosetoleranceandnoninsulindependentdiabetesmellitus AT hiromichiwada effectsofhighlyabsorbablecurcumininpatientswithimpairedglucosetoleranceandnoninsulindependentdiabetesmellitus AT kojihasegawa effectsofhighlyabsorbablecurcumininpatientswithimpairedglucosetoleranceandnoninsulindependentdiabetesmellitus AT tatsuyamorimoto effectsofhighlyabsorbablecurcumininpatientswithimpairedglucosetoleranceandnoninsulindependentdiabetesmellitus |